May Baseline JCV Status Influence the MS Clinical Evolution During Natalizumab Treatment? Evidence From a Multicenter-2 Years-Prospective Study

Multiple Sclerosis and Demyelinating Disorders - United Kingdom
doi 10.1186/s40893-017-0027-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Radiologic MS Disease Activity During Natalizumab Treatment Interruption: Findings From RESTORE

Journal of Neurology
Neurology
2014English

Evolution of Nevi During Treatment With Natalizumab

Archives of Dermatology
2010English

Health Status of Sarcoidosis Patients in Baseline and in 10 Years Under Different Treatment Strategies (Multicenter Analysis)

Pulmonologiya
PulmonaryRespiratory Medicine
2012English

A Multicenter Prospective Randomized Clinical Trial Assessing Implant Design Modifications After 3 Years

Clinical Oral Implants Research
Oral Surgery
2017English

Coordination and Management of Multicenter Clinical Studies in Trauma: Experience From the PRospective Observational Multicenter Major Trauma Transfusion (PROMMTT) Study

Resuscitation
Emergency NursingEmergency MedicineCardiovascular MedicineCardiology
2012English

Correction To: Switching From Natalizumab to Fingolimod Treatment in Multiple Sclerosis: Real Life Data From the Austrian MS Treatment Registry

Journal of Neurology
Neurology
2019English

Clinical Baseline Factors Predict Response to Natalizumab: Their Usefulness in Patient Selection

BMC Neurology
MedicineNeurology
2014English

Treatment of Accidental Hypothermia: A Prospective Clinical Study.

BMJ
1980English

Clinical Benefit of Basal Insulin Analogue Treatment in Persons With Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy